PF

Pfizer Inc

PFE · BA · Healthcare / Drug Manufacturers - General

$11,190+130.00 (+1.18%)

Close Sep 22, 2026 · end-of-day

Market Stats

Previous Close$11,060
Open$11,020
Day Range$10,970 – $11,200
52-Week Range$8,050 – $11,680
Volume12.55K
Market Cap$31.32T
P/E (TTM)5.17
Forward P/E1.28
EPS$2,125.51
Dividend Yield5.75%
Beta0.28
50-Day Avg$10,902.8
200-Day Avg$10,074.25

Price History

Open in new tab
Loading price history…

About

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Company Details

Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Dr. Albert Bourla D.V.M., Ph.D.
Employees
75.00K
Headquarters
66 Hudson Boulevard East, New York, NY, United States, 10001-2192, Argentina
Website
https://www.pfizer.com

Leadership

  • Dr. Albert Bourla D.V.M., Ph.D.Chairman of the Board & CEO · b. 1962
  • Dr. Chris Boshoff FMedSci, M.D., Ph.D.Chief Scientific Officer and President of Research & Development · b. 1964
  • Mr. Douglas M. LanklerExecutive VP & Chief Legal Officer · b. 1966
  • Mr. Aamir MalikExecutive VP & Chief U.S. Commercial Officer · b. 1976
  • Ms. Cecile GueganInterim CFO & Executive VP · b. 1971
  • Ms. Jennifer B. DamicoSenior VP, Controller & Principal Accounting Officer · b. 1969
  • Mr. Dennis P. HancockExecutive VP & Chief Information Officer
  • Ms. Francesca M. DeMartinoChief Investor Relations Officer
  • Ms. Payal Sahni BecherChief People Experience Officer & Executive VP · b. 1975
  • Dr. Michael S. Vincent M.D., Ph.D.Senior VP and Chief Scientific Officer of Inflammation & Immunology

Financials

Income Statement

Line item2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue$53.65B$51.75B$41.91B$81.29B$100.33B$59.55B$63.63B$62.58B
Cost of Revenue$11.25B$10.22B$8.69B$30.82B$34.34B$24.95B$17.85B$16.07B
Gross Profit$42.40B$41.53B$33.22B$50.47B$65.99B$34.60B$45.78B$46.51B
Operating Income$15.04B$13.92B$8.76B$20.23B$37.27B$4.42B$14.94B$17.41B
EBITDA$19.59B$25.27B$13.72B$30.79B$39.58B$9.56B$18.13B$16.78B
Net Income$11.15B$16.27B$9.62B$21.98B$31.37B$2.12B$8.03B$7.77B
R&D$8.01B$8.65B$9.40B$13.83B$11.43B$10.68B$10.82B$10.44B
Interest Expense$1.32B$1.57B$1.45B$1.29B$1.24B$2.21B$3.09B$2.67B

Balance Sheet

Line item2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets$159.42B$167.49B$154.23B$181.48B$197.21B$226.50B$213.40B$208.16B
Total Liabilities$95.66B$104.04B$90.76B$104.01B$101.29B$137.21B$124.90B$121.39B
Total Equity$63.41B$63.14B$63.24B$77.20B$95.66B$89.01B$88.20B$86.48B
Cash$1.14B$1.30B$1.78B$1.94B$416.00M$2.85B$1.04B$1.14B
Net Debt$40.60B$50.84B$38.05B$36.49B$34.45B$67.99B$62.61B$62.82B

Cash Flow

Line item2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow$15.83B$12.59B$14.40B$32.58B$29.27B$12.04B$12.74B$11.70B
Investing Cash Flow$4.53B$-3.94B$-4.27B$-22.55B$-15.78B---
Financing Cash Flow$-20.44B$-8.48B$-9.65B$-9.82B$-14.83B$15.61B$-17.14B$-10.30B
Capital Expenditure$1.98B$2.05B$2.23B$2.71B$3.24B$3.86B$2.91B$2.63B
Free Cash Flow$13.63B$9.99B$11.61B$29.87B$26.03B$8.18B$9.84B$9.07B
Dividends Paid$7.98B$8.04B$8.44B$8.73B$8.98B$9.18B$9.51B$9.77B

Key Statistics & Ratios

Market Cap
$31.32T
Enterprise Value
$321.19T
Trailing P/E
5.17
Forward P/E
1.28
PEG Ratio
1.71
Price / Sales
491.71
Price / Book
0.25
EPS
$2,125.51
Book Value
$5,687.98
Revenue (TTM)
$63.70B
Gross Profit (TTM)
$47.59B
EBITDA
$25.38B
Profit Margin
6.80%
Operating Margin
27.88%
Return on Equity
5.01%
Return on Assets
5.78%
Shares Outstanding
2.85B
Shares Float
22.77B
Beta
0.28
Dividend Yield
5.75%
Dividend Rate
$648.77
Payout Ratio
28.29%

Dividends

20194×
$0.18Nov 7, 2019$0.18Aug 1, 2019$0.18May 9, 2019$0.18Jan 31, 2019
20184×
$0.17Nov 8, 2018$0.17Aug 2, 2018$0.17May 10, 2018$0.17Feb 1, 2018
20174×
$0.16Nov 9, 2017$0.16Aug 2, 2017$0.16May 10, 2017$0.16Feb 1, 2017
20164×
$0.15Nov 8, 2016$0.15Aug 3, 2016$0.15May 11, 2016$0.15Feb 3, 2016
20154×
$0.14Nov 4, 2015$0.14Aug 5, 2015$0.14May 6, 2015$0.01Feb 4, 2015
20144×
$0.13Nov 5, 2014$0.13Jul 30, 2014$0.13May 7, 2014$0.13Feb 5, 2014